Yes, Loxo is still plan­ning on seek­ing an ac­cel­er­at­ed OK, in case you had for­got­ten

Back in the spring, Loxo On­col­o­gy $LOXO was ready to pounce with an ear­ly snap­shot of some clin­i­cal re­spons­es to its lead can­cer drug, a com­mon strat­e­gy among small pub­lic biotechs look­ing to raise their pro­file – and cash. Not sur­pris­ing­ly, it al­so im­me­di­ate­ly mapped out a plan to set up its Phase II study as a reg­is­tra­tional study, SOP among biotechs cap­i­tal­iz­ing on the FDA’s open arms for quick ap­provals, when the ear­ly da­ta are right.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER